Seelos therapeutics receives positive ema opinion on orphan drug designation for sls-005 (trehalose) in amyotrophic lateral sclerosis (als)

New york, april 20, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on european orphan drug designation for sls-005 in amyotrophic lateral sclerosis (als) from the european medicines agency (ema) committee for orphan medicinal products (comp). the positive opinion issued by comp will be sent to the european commission, which is expected to grant the orphan designation within 30 days.
SEEL Ratings Summary
SEEL Quant Ranking